Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xilio Therapeutics, Inc. - Common Stock
(NQ:
XLO
)
8.910
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xilio Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
September 28, 2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
August 12, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
↗
September 09, 2025
Via
Stocktwits
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 02, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...
Via
Finterra
Topics
Lawsuit
Xilio Therapeutics Announces Pricing of Underwritten Offering
February 11, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
January 08, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
November 13, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 10, 2025
Via
Benzinga
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 07, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 07, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
October 30, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
October 03, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
September 09, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Revenue Jumps 246 Percent in Q2
↗
August 14, 2025
Via
The Motley Fool
Topics
Intellectual Property
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
August 14, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
